Illustration: Axios Visuals
Gilead (Nasdaq: GILD) agreed to buy privately held oncology biotech Tubulis in a deal worth up to $5 billion, the companies announced Tuesday.
Why it matters: It's Gilead's third deal in the last three months, as Big Pharma embarks on an acquisition spree to refill pipelines.
